MDXH
$3.36
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally.
Intraday
Recent News
MDxHealth S.A. Q4 2025 Earnings Call Summary
Moby summary of MDxHealth S.A.'s Q4 2025 earnings call
MDxHealth SA (MDXH) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amid Rising Losses
MDxHealth SA (MDXH) reports a 19% revenue increase and significant unit growth, but faces challenges with increased losses and cash flow concerns.
MDxHealth (MDXH) Q4 2025 Earnings Call Transcript
Michael McGarrity: Thanks, John, and thank you all for joining us for our fourth quarter and full year 2025 earnings conference call for MDxHealth S.A. With me today is Ron Kalfus, who has returned as our Interim Chief Financial Officer. Over the past few years, operating discipline, commercial execution, and an aggressive growth strategy have positioned MDxHealth S.A. as the leader in precision diagnostics focused in urology.
MDxHealth Q4 Earnings Call Highlights
MDxHealth (NASDAQ:MDXH) reported fourth-quarter and full-year 2025 results and provided 2026 guidance, with management highlighting continued revenue growth, ongoing integration work following the ExoDx acquisition, and expectations for improving profitability over the course of 2026. Management fr
Loss-Making MDxHealth SA (NASDAQ:MDXH) Expected To Breakeven In The Medium-Term
With the business potentially at an important milestone, we thought we'd take a closer look at MDxHealth SA's...